anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: This case report describes the successful use of imiquimod to treat genital herpes in an immunocompetent individual with acyclovir-resistant HSV.
CASE REPORT: A 32 year old male patient, presented with asymptomatic non-healing ulcers over the genital region for 2 years. The ulcers initially responded to acyclovir but became persistent after a few months. He also received multiple courses of antibiotics. On examination, the patient had bilateral inguinal lymphadenopathy and multiple painless ulcers over the coronal sulcus. Routine investigations were normal. The patient was treated with oral and intravenous acyclovir but showed no response. He was then started on topical imiquimod cream applied on alternate days. After one week, the patient presented with pain, redness, burning sensation, and fresh ulcer over the glans which were suspected to be imiquimod-induced irritant reaction or ulcer. Imiquimod was withheld for one week and then restarted at a twice-weekly schedule. After 1 month and 7 days of treatment with imiquimod at a twice-weekly schedule, there was healing of the ulcers.
CONCLUSION: This case report illustrates the efficacy of imiquimod cream as a topical treatment for genital herpes simplex in an immunocompetent patient who had previously been unresponsive to treatment with acyclovir.
Concomitant use of benzodiazepines, including Chlordiazepoxide Hydrochloride/Clidinium Bromide, and opioids may result in profound sedation, respiratory depression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs for use in patients for who alternative treatment options are inadequate.

Observational studies have demonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe Chlordiazepoxide Hydrochloride/Clidinium Bromide capsules concomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation.

Advise both patients and caregivers about the risks of respiratory depression and sedation when Chlordiazepoxide Hydrochloride/Clidinium Bromide is used with opioids (see PRECAUTIONS).

As in the case of other preparations containing CNS-acting drugs, patients receiving Chlordiazepoxide Hydrochloride/Clidinium Bromide should be cautioned about possible combined effects with opioids, alcohol and other CNS depressants. For the same reason, they should be cautioned against hazardous occupations requiring complete mental alertness, such as operating machinery or driving a motor vehicle.
Both acute pain and opioid administration have been shown to induce a systemic pro-inflammatory response. However, the presence of these inflammatory responses is unknown in situations where a co-occurrence of pain and opioid administration exists as is the common clinical case of a patient with acute pain and taking opioid analgesics. A patient population for whom the combined effects of pain and opioids on immune function are particularly complex are the estimated 5.2 million Americans aged 12 or older who abuse prescription opioids. Not only are these individuals at risk for poor pain management due to their status as an "addict", but there is good preclinical evidence to suggest that their chronic opioid use brings with it a general state of systemic inflammation, and thus setting the patient up for a unique or enhanced inflammatory response to the combination of acute opioids and pain. To better understand the health implications of treating acute pain with opioids in patients and in particular, those who abuse prescription opioids, inflammatory responses to the main and interaction effects of acute pain and opioid administration will be examined in well-characterized samples of each. Specifically, we will evaluate the inflammatory and cytokine responses to: (1) experimental pain; (2) an acute opioid challenge; and (3) the combination of opioid administration followed by cold-pressor pain, in healthy control subjects and age- and gender-matched prescription opioid abusers.
This review examines how various medications can trigger inflammation throughout the body. It explores causes, ranging from common pain relievers like NSAIDs to chemotherapy drugs. The review also highlights potential treatments, including established medications and promising new therapies. Physicians and patients can work together to reduce this risk by understanding these causes and implementing preventive measures, such as monitoring for side effects and using alternative medications when possible. Drug-induced inflammation can be categorized into four types based on the immune response involved. Symptoms vary by type and affected organ. Common symptoms include fever, malaise, joint pain, rash, and swelling. Diagnosis involves blood tests, imaging, and biopsies. Treatment primarily involves discontinuing the suspected drug and providing supportive care. The development of new drugs and therapies has made diagnosis challenging. However, recent advances in biomarkers and genetic risk assessment techniques are improving diagnosis and risk assessment of drug-induced liver injury. Preventive measures for drug-induced inflammation include monitoring for side effects, using alternative medications, developing new drug delivery methods, exploring new anti-inflammatory drugs, being aware of rare side effects, and understanding the underlying mechanisms.
OBJECTIVES: This study investigated the potential effects of perfluoroalkyl substance (PFAS) in serum on MAFLD, NAFLD, and liver fibrosis.
METHODS: Our sample included 696 participants (≥ 18 years) from the 2017-2018 NHANES study with available serum PFASs, covariates, and outcomes. Using the first quartile of PFAS as the reference group, we used weighted binary logistic regression and multiple ordered logistic regression used to analyze the relationship between PFAS and MAFLD, NAFLD, and liver fibrosis and multiple ordinal logistic regression to investigate the relationship between PFAS and MAFLD, NAFLD, and liver fibrosis and calculated the odds ratio (OR) and 95% confidence interval for each chemical. Finally, stratified analysis and sensitivity analysis were performed according to gender, age, BMI, and serum cotinine concentration.
RESULTS: A total of 696 study subjects were included, including 212 NAFLD patients (weighted 27.03%) and 253 MAFLD patients (weighted 32.65%). The quartile 2 of serum PFOA was positively correlated with MAFLD and NAFLD (MAFLD, OR 2.29, 95% CI 1.05-4.98; NAFLD, OR 2.37, 95% CI 1.03-5.47). PFAS were not significantly associated with liver fibrosis after adjusting for potential confounders in MAFLD and NAFLD. Stratified analysis showed that PFOA was strongly associated with MAFLD, NAFLD, and liver fibrosis in males and obese subjects. In women over 60 years old, PFHxS was also correlated with MAFLD, NAFLD, and liver fibrosis.
CONCLUSION: The serum PFOA was positively associated with MAFLD and NAFLD in US adults. After stratified analysis, the serum PFHxS was correlated with MFALD, NAFLD, and liver fibrosis.
Disclosed herein are embodiments of a composition comprising a drug in a polymer nanoparticle. The nanoparticles may have a size and/or a surface potential selected to facilitate lymph node uptake and/or dissemination throughout the lymphatic system. The nanoparticle may be a polyethyleneglycol-block-poly(ε-caprolactone) (PEG-PCL) nanoparticle. Also disclosed are embodiments of a method of using the composition. The composition may be administered subcutaneously. The drug-loaded nanoparticles are useful for treating certain cancers and/or decreasing the number of melanocytes in lymph nodes that are proximal to, distal to or both proximal and distal to a site of administration.
PURPOSE: A cosmetic composition containing Brasenia schreberi J.F. Gmel. is provided to enhance collagen synthesis and to ensure antioxidation without side effect. CONSTITUTION: A cosmetic composition for anti-wrinkling contains 0.1-10 wt% of Brasenia schreberi J.F. Gmel. and additionally contains conventional cosmetic ingredients. The cosmetic composition is formed in an aqueous phase or oil phase. The aqueous phase additionally contains moisturizer, purified water, bivalent metal salt, hydrophilic non-ionic surfactant, or water solution polymers. The oil phase additionally contains higher alcohol, oil-soluble polymers, ceramide or derivative thereof, and cholesterol or derivative thereof.
SASH1 (SAM and SH3 domain containing 1) has been increasingly reported as a tumor suppressor gene. However, there is limited research on the role of SASH1 in breast cancer. This manuscript aims to investigate the mechanism of SASH1 in the occurrence, development, and prognosis of breast cancer. Firstly, we obtained RNA-sequencing data of the tumors from the Genomic Data Commons data portal website, along with the corresponding clinical information of patients. Pan-cancer analysis was performed to analyze the expression of SASH1 across all tumors. Univariate Cox regression analysis was used to assess the correlation between SASH1 expression and the prognosis of breast cancer patients. Then, immunohistochemistry was utilized to evaluate the expression levels of SASH1, p-Akt, p-PI3K, and p-mTOR in breast cancer tissue. Finally, a cell assay was employed to analyze the impact of SASH1 on the proliferation and invasion of breast cancer cells (MDA-MB-231). The results revealed that SASH1 expression is decreased in BRCA, LUSC, LUAD, CESC, ESCA, and COAD. Meta-analysis also found that SASH1 is downregulated in most tumor tissues, and the expression level of SASH1 in breast cancer was significantly lower than that in the control group (OR = 0.14, 95% CI = 0.08-0.25; P < 0.001). Further experimental validation showed that SASH1 expression is significantly downregulated in breast cancer tissue (38.33%, 23/60), and the overexpression of SASH1 can inhibit the proliferation and invasion of breast cancer cells accompanied by the suppression of PI3K-Akt-mTOR signaling pathway. Additionally, SASH1 overexpression can improve OS and RFS of breast cancer patients.
A convergent parallel mixed methods design with qualitative data collection embedded in a quasi-experimental study was developed to examine the potential of three modalities of preparation for hospital discharge of the families of children with chronic diseases in terms of uncertainty levels and management of the disease at home. Caregivers of these children were divided into three groups: two experimental groups and one control group. Two scales were applied: one measured family management, and the other evaluated uncertainties in relation to the disease. In addition, an in-depth interview was conducted. Wilcoxon's test and the integrated response index were used in data analysis to compare performance between the groups. Inductive thematic analysis was employed for the qualitative data. The data were integrated, comparing the groups before and after preparation for hospital discharge. Twenty-five family caregivers completed this study. Data integration showed that the intervention group, in which the families developed planning to prepare for discharge in a dialogical way with professionals, presented better perceptions regarding care management when compared to structured guide and usual care groups. Participation of families in planning for hospital discharge showed a reduction in uncertainties regarding the disease and better care management of children at home.
The invention discloses a marker and a system for determining tumor radiotherapy sensitivity. The inventor finds that the HOXA1 high expression is closely related to the radiation resistance of head and neck squamous carcinoma, low-grade glioma and nasopharyngeal carcinoma through researches. Patients with high HOXA1 expression had an elevated risk of recurrence after radiotherapy and a poorer prognosis. Tumor radiotherapy sensitivity can be predicted by detecting HOXA1 expression levels. The radiation sensitivity of the nasopharyngeal carcinoma cells can be remarkably improved by inhibiting the HOXA1 expression of the nasopharyngeal carcinoma cells through the interfering RNA. Inhibition of HOXA1 expression may be used for tumour radiosensitization.
Coronary artery disease is the first cause of death related to atherothrombosis. There is a close correlation between the extension of coronary artery disease and the severity of atherosclerotic lesions in extra coronary arterial beds. In addition, these symptomatic extracoronary lesions dramatically decrease the survival of these patients. However, scant data are available regarding the prevalence of extracoronary asymptomatic lesions. Conversely, the annual absolute risk of these lesions remains unknown. Consequently, whether a systematic identification of these extracoronary asymptomatic lesions is relevant remains to be established. The Primary Objective and Primary Endpoint of the AMERICA study is to demonstrate the superiority of an active detection and management of the extension of atherothrombosis in high Risk coronary patients (active strategy) in comparison with standard of care for coronary atherosclerosis (conservative strategy).
PCT No. PCT/EP93/01289 Sec. 371 Date Jun. 16, 1995 Sec. 102(e) Date Jun. 16, 1995 PCT Filed May 21, 1993 PCT Pub. No. WO93/24110 PCT Pub. Date Dec. 9, 1993According to the present invention, there is provided a continuous method for the production of retarded pharmaceutical compositions by an extrusion process. A mixture of an active material, a low and high melting lipid or lipoid components is introduced by means of an extruder screw conveyor into a preheated extruder and brought to a temperature which is at most about 4 DEG  C. above the melting temperature of the low melting component at a pressure of about 200 to about 600 kPa(N/m2). The mass is extruded through a nozzle plate with a nozzle diameter of about 1.2 to about 4 mm and subsequently cooled, and if desired, granulated.
BACKGROUND AND OBJECTIVES: Massive transfusion protocols (MTPs) are critical in managing haemorrhage, yet their utilization varies. There is lack of data on the utilization of MTPs in the Middle East and North Africa (MENA) region. This study aims to assess the degree of utilization of MTPs in the region.
MATERIALS AND METHODS: We conducted a survey to collect data on MTP use, inviting medical directors of transfusion services from various hospitals. Data were analysed to determine the prevalence of MTP utilization, their compositions, challenges in application and areas of future need.
RESULTS: Eighteen respondents participated, representing 11 countries in the region. Thirteen hospitals implemented MTP, and eight included paediatrics. Eleven institutions used more than one definition of massive haemorrhage, with the most common being ≥10 red blood cell (RBC) units transfused for adults and replacement of >50% total blood volume in paediatrics. The majority of sites with MTPs utilized 1:1:1 RBCs:platelets:plasma ratio (70%). Variations were observed in the types and blood groups of components used. Two sites utilized whole blood, while six are considering it for future use. Utilization of adjunctive agents and frequency of laboratory testing varied among the sites. Challenges included the lack of medical expertise in protocol development, adherence and paediatric application. The need assessment emphasized the need for developing regional guidelines, standardized protocols and training initiatives.
CONCLUSION: Although several hospitals have adopted MTPs, variations exist in activation criteria, blood product ratios and monitoring. Challenges include the lack of medical expertise, protocol adherence and addressing paediatric needs. Standardizing protocols, enhancing training and paediatric application are crucial for improving massive transfusion management in the region.
Patients receive celecoxib PO BID, recombinant interferon alfa-2b IV over 20 minutes, and rintatolimod IV on days 1-3 of weeks 1-3, as well as paclitaxel IV over 1 hour once weekly on day 1. Treatment continues for a total of 12 weeks in the absence of disease progression or unacceptable toxicity. 1-3 weeks after last dose of paclitaxel, patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes. Treatment repeats every 2 weeks for 4 cycles in the absence of disease progression or unacceptable toxicity.
A blockchain-based travel security system is provided. The system increases travel security. The system includes an electronically stored user's itinerary file with a user's pre-registered travel itinerary. The itinerary file can be stored on a blockchain. The system also includes an electronically stored user's medical history file stored on the blockchain. A single trusted information source provides the itinerary file and the medical history file to the blockchain. The system includes a dual track information storage and retrieval system which is configured to store the itinerary file and to store the recent medical history file. The dual track information storage and retrieval system comprises a first track related to the user's recent medical history file and a second track related to the itinerary file.
Patients will be included during admittance in the acute psychiatric ward or when in contact with the outpatient team for acute and emergency psychiatry. They will receive acute treatment and be placed on a waiting list until enough patients are included to start the intervention. Then the included patients will be randomized to either the psychoeducational course or the individual session. The course and the individual lessons start at the same time. Each group includes 8-10 participant to receive a group based psychoeducative intervention (three for patients, one for next of kin) and TAU.

The first session (2x45 min) focus on information on suicidal thoughts, mental pain, suicide attempts and suicide as a phenomenon with focus on vulnerability factors, risk development and development of the suicidal crisis syndrome. The second session (2x45 min) tackles identifying triggers for increase in suicide risk and suicidal impulses, detecting early warning signals for increased suicide risk and how to recognize the change as it happens. In the third session (3x45 min) patients work on completing the individual safety plan to prevent an increase in suicide risk. The plan includes "situations that may trigger increased risk", "how to recognize and communicate the increased risk" and "actions that may reduce or increase risk." Finally, the fourth and last session (2x45 min) is aimed at the next of kin that the group participant wants to attend. Patients do not attend this session. The next of kin receive a review of the information from the first two sessions, as well as focus on what the next of kin can or cannot do to help if the risk of suicide increases.

The control group receive one individual session with focus on suicide risk and safety plan with a psychologist or physician and TAU.

Randomization and masking of study groups Participants will be equally randomized (1:1) in the intervention and control group. Patients will be included during admittance in the acute psychiatric ward or when in contact with the outpatient team for acute and emergency psychiatry. The first randomization takes place when sixteen to twenty participants are included. Randomization will take place by manual randomization by an external person at the Research department at St. Olav Hospital in Trondheim. This ensures an equal distribution between the intervention group and the control group. The patient and treating clinician will be unblinded to treatment modality. To compensate for lack of blinding concerning the received treatment, the persons ratings, subsequent measurements and data collection at follow-up will be blinded to the treatment conditions to avoid confirmation bias. The statistical advisor will also be blinded to treatment modality.
A computer system for processing and displaying medical data is provided. Health data pertaining to a user is received. The received health data is analyzed with respect to a set of active clinical guidelines. Medical diagnosis results are provided to the user based on the analyzed data. The received health data and the medical diagnosis results are displayed to the user via a mobile device. The mobile device is further configured to provide a plurality of health related services.
PURPOSE:A cosmetic for the hair or skin, containing a cationic surfactant and a specific fractionated substance of an aloe, capable of suppressing the irritation of the cationic surfactant to the skin and membranes, and improving particularly the conditioning property for the hair. CONSTITUTION:A cosmetic containing (A) 0.001-30wt% cationic surfactant and (B) 0.01-10wt% specific fractionated substance of an aloe. The cosmetic has high keeping quality without problem of coloring or discoloring, etc. A quaternary ammonium salt type surfactant of formula I [R1 or R1 and R2 are 10-24C alkyl, hydroxyalkyl or R(OCH2CH2)1-10 (R is 10-24C alkyl, etc.); R2-R4 or R3 and R4 are 1-3C alkyl or group of formula II (n is a number 1-5; R5 is H or CH3); X is halogen, etc.] is preferred for the component (A). The component (B) is obtained by treating an aloe tree sap with activated carbon and if necesary heat-treating and/or extracting the tree sap with an organic solvent.
The traditional Stanford DSMP is conducted in this control group. Participants in the FP group will first attend a 7-session community health and safety curriculum as a partial attention control intervention, followed by the Stanford DSMP and Diabetes Resource Seminar facilitated by the local public health department.
An audio signal processor treats a digitally encoded signal. Units (3, 12) sample the encoded signal and units (8, 13) calculate from the sampled values a correlation function relevant to a particular time frame. The function value serves to control an adaptive echo cancellation algorithm. The sampled signal portions are truncated (2, 5) so that only the arithmetic sign bit of each signal portion contributes to the function calculation. An incoming signal sample is initially treated in an extraction block arranged to determine the arithmetic sign relevant to that signal, the resulting sign bits being fed in sequence to a shift register arranged to store a predetermined number of sign bits. Outputs are provided from selected locations in the register in accordance with a control logic select circuit.